Companies › Orna Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ORN252 circular RNA encoding anti-CD19 CAR protein in lipid nanoparticle | CD19 | Phase 1 | Healthy Volunteers - Male and Female | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07439796 | ORN252 | Phase 1 | Healthy Volunteers - Male and Female | Other | Dec 2026 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.